Phibro Animal Health (NASDAQ:PAHC) Given New $50.00 Price Target at JPMorgan Chase & Co.

Phibro Animal Health (NASDAQ:PAHC) had its target price hoisted by JPMorgan Chase & Co. from $45.00 to $50.00 in a research report released on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other brokerages have also recently issued reports on PAHC. Morgan Stanley set a $34.00 price objective on shares of Phibro Animal Health in a report on Thursday, August 28th. Weiss Ratings upgraded Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Bank of America raised their price objective on Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research note on Friday, August 29th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Phibro Animal Health has an average rating of “Hold” and a consensus target price of $31.40.

Phibro Animal Health Stock Up 1.7%

Shares of Phibro Animal Health stock traded up $0.72 during trading on Friday, hitting $43.76. 380,597 shares of the stock traded hands, compared to its average volume of 277,290. The stock has a market cap of $1.77 billion, a P/E ratio of 37.09, a PEG ratio of 1.24 and a beta of 0.81. The company has a fifty day moving average price of $39.71 and a two-hundred day moving average price of $30.85. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. Phibro Animal Health has a twelve month low of $16.16 and a twelve month high of $44.35.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The business had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities research analysts predict that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 annualized dividend and a yield of 1.1%. Phibro Animal Health’s dividend payout ratio (DPR) is 40.68%.

Insider Activity at Phibro Animal Health

In related news, CEO Jack Bendheim sold 16,075 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $40.38, for a total transaction of $649,108.50. Following the completion of the transaction, the chief executive officer directly owned 23,899 shares in the company, valued at $965,041.62. The trade was a 40.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 67,336 shares of company stock valued at $2,734,588 in the last three months. 50.13% of the stock is currently owned by company insiders.

Institutional Trading of Phibro Animal Health

Several hedge funds have recently added to or reduced their stakes in PAHC. National Bank of Canada FI bought a new position in shares of Phibro Animal Health in the first quarter worth approximately $30,000. Financial Management Professionals Inc. bought a new stake in Phibro Animal Health during the 2nd quarter valued at approximately $32,000. EverSource Wealth Advisors LLC grew its stake in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after purchasing an additional 2,685 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Phibro Animal Health by 768.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock worth $118,000 after buying an additional 4,079 shares during the period. Finally, Quantbot Technologies LP lifted its holdings in shares of Phibro Animal Health by 53.8% during the first quarter. Quantbot Technologies LP now owns 7,870 shares of the company’s stock valued at $168,000 after purchasing an additional 2,754 shares during the last quarter. 99.34% of the stock is owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.